Department of Orthopedic Surgery, University of Virginia, Charlottesville, VA, USA.
Oregon Health & Science University, Portland, OR, USA.
Cartilage. 2023 Jun;14(2):152-163. doi: 10.1177/19476035231157335. Epub 2023 Feb 23.
Up to 10 million Americans below the age of 65 years have symptomatic knee osteoarthritis (OA) and may not yet be candidates for arthroplasty. In response, a subcutaneous implantable shock absorber (ISA) that unloads the knee has been developed. The safety and effectiveness of ISA treatment were compared against a surgical unloading control, high tibial osteotomy (HTO).
This was a prospective open-label cohort study with a historical control arm. Subjects underwent ISA placement or HTO. The primary endpoint was a composite variable combining pain, function, specific adverse events, integrity of implant or hardware, and conversion to subsequent surgery. Pain and function outcomes (Western Ontario and McMaster Universities Arthritis Index scores) were assessed through 24 months. Adverse events were tracked.
The primary endpoint demonstrated superiority of the ISA arm versus the HTO arm, with 85.6% of ISA subjects meeting all criteria compared with 65.5% of HTO subjects. In addition, all 5 secondary endpoints showed superiority of ISA over HTO. At 24 months, the proportions of subjects considered responders were 95.8% (ISA) versus 87.9% (HTO) for pain and 91.7% (ISA) versus 81.3% (HTO) for function. The ISA procedure was well tolerated, with 13.4 days to full weightbearing status versus 58.0 days for the HTO arm.
Treatment with an ISA demonstrated noninferiority and superiority versus treatment with HTO in subjects aged 25-65 years who had OA of the medial knee. Treatment with ISA has high clinical benefit and is durable through at least 24 months.
多达 1000 万年龄在 65 岁以下的美国人患有症状性膝骨关节炎(OA),可能还不是关节置换术的候选者。因此,已经开发出一种可减轻膝关节负荷的皮下可植入式减震器(ISA)。ISA 治疗的安全性和有效性与手术减压对照(HTO)进行了比较。
这是一项前瞻性开放标签队列研究,具有历史对照臂。受试者接受 ISA 植入或 HTO。主要终点是一个复合变量,结合疼痛、功能、特定不良事件、植入物或硬件的完整性以及随后手术的转换。通过 24 个月评估疼痛和功能结果(西部安大略省和麦克马斯特大学关节炎指数评分)。跟踪不良事件。
主要终点表明 ISA 臂优于 HTO 臂,ISA 组有 85.6%的受试者符合所有标准,而 HTO 组有 65.5%的受试者符合所有标准。此外,所有 5 个次要终点均显示 ISA 优于 HTO。在 24 个月时,考虑到疼痛的应答者比例分别为 95.8%(ISA)和 87.9%(HTO),而考虑到功能的应答者比例分别为 91.7%(ISA)和 81.3%(HTO)。ISA 手术耐受性良好,完全负重状态的时间为 13.4 天,而 HTO 组为 58.0 天。
在年龄在 25-65 岁、内侧膝关节 OA 的受试者中,ISA 治疗与 HTO 治疗相比,非劣效性和优越性。ISA 治疗具有较高的临床获益,至少 24 个月内具有持久性。